Correction (JACC: Heart Failure (2015) 3(1) (22–29), (S2213177914003795), (10.1016/j.jchf.2014.07.009));Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina

JACC: Heart Failure

Volumn 3, Issue 1, 2015, Pages 22-29

  Greenberg, Barry H ^a   Chou, Willis ^b   Saikali, Khalil G ^b   Escandón, Rafael ^b   Lee, Jacqueline H ^b   Chen, Michael M ^b   Treshkur, Tatyana ^c   Megreladze, Irakli ^d   Wasserman, Scott M ^e   Eisenberg, Paul ^e   Malik, Fady I ^b   Wolff, Andrew A ^b   Shaburishvili, Tamaz ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Cytokinetics Inc   (United States)

^c ALMAZOV NATIONAL MEDICAL RESEARCH CENTRE   (Russian Federation)

^d Cardiology Clinic   (United States)

^e AMGEN INC   (United States)

^f Diagnostic Services Clinic   (United States)

Author keywords

Exercise tolerance; Heartfailure; Ischemic cardiomyopathy; Omecamtiv mecarbil

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE MB; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEART ENZYME; OMECAMTIV MECARBIL; PLACEBO; SPIRONOLACTONE; TROPONIN I; UREA;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGINA PECTORIS; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EXERCISE TOLERANCE; FATIGUE; FEMALE; FEVER; GOUT; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE EXTRASYSTOLE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINUS BRADYCARDIA; ST SEGMENT DEPRESSION; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREADMILL EXERCISE; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; VERY ELDERLY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; DRUG TOLERANCE; EXERCISE; EXERCISE TEST; FOLLOW UP; GEORGIA (REPUBLIC); HEART CONTRACTION; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL ISCHEMIA; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; RUSSIAN FEDERATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANGINA PECTORIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOLERANCE; EXERCISE; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; GEORGIA (REPUBLIC); HUMANS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; RETROSPECTIVE STUDIES; RUSSIA; TREATMENT OUTCOME; UREA;

EID: 84920265115     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2020.06.007     Document Type: Erratum

References (15)

1. Malik F.I., Hartman J.J., Elias K.A., et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 2011, 331:1439-1443.
2. Teerlink J.R., Clarke C.P., Saikali K.G., et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet 2011, 378:667-675.
3. Cleland J.G., Teerlink J.R., Senior R., et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011, 378:676-683.
4. Weber K.T., Kinasewitz G.T., West J.S., Janicki J.S., Reichek N., Fishman A.P. Long-term vasodilator therapy with trimazosin in chronic cardiacfailure. NEngl J Med 1980, 303:242-250.
5. Gibbons R.J., Balady G.J., Bricker J.T., et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002, 40:1531-1540.
6. Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. NEngl J Med 1991, 325:1468-1475.
7. Cohn J.N., Goldstein S.O., Greenberg B.H., et al. Adose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. NEngl J Med 1998, 339:1810-1816.
8. Teerlink J.R., Metra M., Zaca V., et al. Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev 2009, 14:243-253.
9. Cuffe M.S., Califf R.M., Adams K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002, 287:1541-1547.
10. Petersen J.W., Felker G.M. Inotropes in the management of acute heart failure. Crit Care Med 2008, 36:S106-S111.
11. Kass D.A., Solaro R.J. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006, 113:305-315.
12. Teerlink J.R. Anovel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev 2009, 14:289-298.
13. Kokowicz P., Stec S., Flasinska K., Budaj A. Troponin release following exercise test in patients with stable angina pectoris-risk factors and prognostic significance. Kardiologia Polska 2010, 68:414-419.
14. Schulz O., Kromer A. Cardiac troponin I: a potential marker of exercise intolerance in patients with moderate heart failure. Am Heart J 2002, 144:351-358.
15. Mooss A.N., Prevedel J.A., Mohiuddin S.M., Hilleman D.E., Sketch M.H. Effect of digoxin onST-segment changes detected by ambulatory electrocardiographic monitoring in healthy subjects. Am J Cardiol 1991, 68:1503-1506.